Overview

  • Product nameFluvastatin sodium salt
  • Description
    Competitive HMG-CoA reductase inhibitor
  • Biological descriptionCompetitive HMG-CoA reductase inhibitor (IC50 = 40 - 100 nM in human and rat microsomes). Potent inhibitor of vascular smooth muscle cell proliferation in vitro (IC50 = 70 nM).
  • Purity> 99%

Properties

    Applications

    Our Abpromise guarantee covers the use of ab120651 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Abreviews Notes
    Functional Studies Use at an assay dependent concentration.

    Fluvastatin sodium salt images

    • ab90529 staining cytochrome C in HepG2 cells treated with fluvastatin sodium salt (ab120651), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of fluvastatin sodium salt, as described in literature.
      The cells were incubated at 37°C for 48 hours in media containing different concentrations of ab120651 (fluvastatin sodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

    References for Fluvastatin sodium salt (ab120651)

    This product has been referenced in:
    • Yang J  et al. The cardioprotective effect of fluvastatin on ischemic injury via down-regulation of toll-like receptor 4. Mol Biol Rep 38:3037-44 (2011). Read more (PubMed: 20127518) »
    • Turner NA  et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol 50:458-61 (2007). Read more (PubMed: 18049315) »
    • Morikawa-Futamatsu K  et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci 79:1380-90 (2006). Read more (PubMed: 16712874) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120651.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"